Myeloproliferative neoplasms
A group of slow-growing diseases in which the bone marrow makes too many red blood cells, white blood cells or platelets. Too many red blood cells make the blood thick, and extra blood cells can make clots form, which can raise the risk of stroke or heart attack. For polycythaemia vera, treatment can include removing some blood, daily low-dose aspirin, or medicines such as hydroxycarbamide that lower the number of red blood cells. Polycythaemia vera, one of the main types, usually starts later in life, on average at 60.
Read more about myeloproliferative neoplasmsTrial-stage treatments and research studies you can joinOpen trials for referral
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Filters
- Tests pelabresib with ruxolitinib in adults with myelofibrosis
Tests pelabresib plus ruxolitinib in adults with myelofibrosis not yet treated with JAK inhibitors.
Aachen, GermanyAlso Dresden, Erlangen, Essen, Hamburg, Hanover, Jena, MannheimAge 18+ - Tests INCA036978 for safety in people with myeloproliferative neoplasms
Tests INCA036978, alone or with standard therapy, in adults with myeloproliferative neoplasms.
Aachen, GermanyAlso Berlin, Freiburg im Breisgau, Halle, MainzAge 18+ - Tests INCA033989 Against Standard Care in Essential Thrombocythemia
Tests INCA033989 against standard treatment in adults with essential thrombocythemia and a CALR mutation.
Aachen, GermanyAlso Berlin, Dresden, Freiburg im Breisgau, Halle, Hamburg, Hanover, Homburg, Jena, …Age 18+ - Tests bomedemstat against usual treatments for polycythemia vera
Compares bomedemstat with usual treatments in adults with polycythemia vera not helped by hydroxyurea.
Dresden, GermanyAlso Essen, HanoverAge 18+ - Long-term asciminib treatment for people with chronic myeloid leukemia
Tests asciminib long term in people with chronic myeloid leukemia who finished an earlier study.
Aachen, GermanyAlso Augsburg, Bad Saarow, Berlin, Bonn, Chemnitz, Dresden, Erlangen, Frankfurt Am Main, …Age 7 to 100 - Tests elritercept against placebo for anemia in myelofibrosis
Tests elritercept against placebo in adults with myelofibrosis and anemia taking ruxolitinib.
Berlin, GermanyAlso Chemnitz, Freiburg im Breisgau, Jena, Koblenz, MutlangenAge 18+ - Tests JNJ-88549968 in people with CALR-mutated myeloproliferative neoplasms
Tests JNJ-88549968, a new antibody drug, in adults with CALR-mutated blood disorders.
Aachen, GermanyAlso Berlin, Essen, Hanover, Heidelberg, RegensburgAge 18+ - Testing Momelotinib with Luspatercept in Transfusion-Dependent Myelofibrosis
Tests momelotinib with luspatercept in adults with myelofibrosis who need regular blood transfusions.
Essen, GermanyAlso Jena, MannheimAge 18+ - Tests sapablursen with standard care in polycythemia vera
Tests sapablursen added to usual care in adults with polycythemia vera.
Dresden, GermanyAlso Frankfurt, Greifswald, Hamburg, Heidelberg, Jena, Mannheim, Mutlangen, RostockAge 18+ - Tests oral nuvisertib in people with myelofibrosis
Tests oral nuvisertib, its safety and how the body handles it, in adults with myelofibrosis.
GermanyAge 18+ - Tests bezuclastinib in adults with advanced systemic mastocytosis
Tests bezuclastinib in adults with advanced systemic mastocytosis, a rare blood disease.
Aachen, GermanyAlso Freiburg im Breisgau, Lübeck, MannheimAge 18+ - Tests BGB-11417 alone or with azacitidine in myeloid blood cancers
Tests BGB-11417, alone or with azacitidine, in adults with acute myeloid leukemia or MDS.
Leipzig, GermanyAlso UlmAge 18+ - Tests INCA035784 safety in adults with myeloproliferative neoplasms
Tests INCA035784 for safety and tolerability in adults with myeloproliferative neoplasms.
Dresden, GermanyAlso Halle, MainzAge 18+ - Long-term safety of luspatercept in people from earlier luspatercept studies
Continues luspatercept treatment and follow-up in adults with anemia-related blood disorders.
Berlin, GermanyAlso Dresden, Düsseldorf, Halle, Hamburg, Hanover, Leipzig, Mainz, MünchenAge 18+ - Compares givinostat with hydroxyurea in high-risk polycythemia vera
Compares givinostat and hydroxyurea in adults with high-risk polycythemia vera.
Dresden, GermanyAge 18+ - Tests selinexor in people with myelofibrosis and low platelet counts
Tests selinexor in adults with myelofibrosis who have not had JAK inhibitor treatment.
Düsseldorf, GermanyAlso JenaAge 18+ - Tests navtemadlin added to ruxolitinib in myelofibrosis patients with a weak response
Tests navtemadlin with ruxolitinib in adults with myelofibrosis responding poorly to ruxolitinib.
Düsseldorf, GermanyAlso Freiburg im Breisgau, Halle, Hamburg, Hanover, Heidelberg, Jena, Kiel, Leipzig, …Age 18+ - Tasquinimod for myelofibrosis that stopped responding to JAK inhibitors
Tests tasquinimod in adults with myelofibrosis that resists JAK inhibitors.
Aachen, GermanyAge 18+ - Tests TL-895 with ruxolitinib in adults with myelofibrosis
Tests TL-895 combined with ruxolitinib in adults with myelofibrosis, a bone marrow disease.
Düsseldorf, GermanyAlso HalleAge 18+ - Tests selinexor alone in people with myelofibrosis and low platelet counts
Tests selinexor alone in adults with myelofibrosis who have not had JAK inhibitors.
Jena, GermanyAge 18+
Search the publications
The results open on the publications page in a new tab, so this page stays as it is.
Lists with this disease filtered
Where treatment stands
One EU-listed medicine, momelotinib, got its first EU authorisation in January 2024.
Approved: 12
Officially approved for this disease in the EU, the US, Switzerland or France.
Human testing stage: 14
Being tested in people. Many treatments at this stage are never approved.
Animal testing stage: 2
Worked in animals in a study published in the last 12 months. Most treatments at this stage never reach people.
Support organisations
Patient organisations and helplines in Germany, for you and your family.
Myeloproliferative neoplasms organisations in Germany
- Krebsinformationsdienst (KID) des DKFZ
Doctors answer cancer questions by phone or e-mail, free, every day from 8:00 to 20:00.
- Deutsche Krebshilfe
German non-profit cancer charity providing information on cancer types, early detection, prevention, therapy and self-help, and funding research and patient support.
- Leukämie-Online (LeukaNET e.V.)
Patient-run German-language online platform for people with leukaemia, with CML and CLL information areas, active patient forums (including a CLL forum) and CML online seminars.
- MPN-Netzwerk e.V.
German patient network for people with myeloproliferative neoplasms. Member of MPNAN.
General support in Germany
- TelefonSeelsorge Deutschland
Free, anonymous 24/7 crisis and emotional support line across Germany (0800 111 0 111, 0800 111 0 222, 116 123), plus chat and e-mail.
- gesund.bund.de
The German Federal Ministry of Health's portal providing reliable, quality-assured health information on diseases, care and prevention.
- Stiftung Unabhängige Patientenberatung Deutschland (UPD)
Statutory independent foundation giving free advice to patients in Germany on health and health-law questions, including patient rights.
International organisations
- MPN Advocacy & Education International
Nonprofit providing education and advocacy for people living with myeloproliferative neoplasms.
- MPN Research Foundation
Foundation funding research into myeloproliferative neoplasms and supporting the MPN patient community.
Frontlight Community
Myeloproliferative neoplasms community in Germany
People living with myeloproliferative neoplasms and those close to them share what they went through. Posts are not medical advice: ask your doctor about your own treatment.
You need a Frontlight account with a verified e-mail address to comment.
Offer tissue or data
There are three ways to help research move faster.
Approved treatments
13 medicines are approved for myeloproliferative neoplasms in at least one of the places we checked. An approval in one place does not mean the medicine is offered or paid for where you live.
Checked on 18 Nov 2026 in the official lists of the US (FDA), the EU (European Commission and EMA) and Switzerland (Swissmedic), which we read every day. The lists of Japan (PMDA, approvals since April 2004), France (ANSM, medicines approved in France only) and Taiwan (TFDA) were checked on 11 Nov 2026. For Canada (Health Canada) and Singapore (HSA) we checked only whether a medicine is sold there, not what for. The French ratings are the opinions of the HAS Transparency Committee, from the French public medicines database (base de données publique des médicaments, newest opinion 10 Dec 2025). 1 uncertain match is left out. Other countries' own approvals were not checked.
“Miracle cure” fact checker
Social media spreads misinformation. Paste here what you read, and we'll tell you whether there is scientific evidence behind it.
What you paste is checked with AI (Anthropic, USA) and is not stored. Please leave out names and other personal details.
Before you pay for anything, ask three things
- Is there a published study in people?
- Can I have the full price in writing?
- What does my doctor say?
About myeloproliferative neoplasms
Sources: NCI PDQ, NHS, Cancer Research UK, Blood
A group of slow-growing diseases in which the bone marrow makes too many red blood cells, white blood cells or platelets. Too many red blood cells make the blood thick, and extra blood cells can make clots form, which can raise the risk of stroke or heart attack. For polycythaemia vera, treatment can include removing some blood, daily low-dose aspirin, or medicines such as hydroxycarbamide that lower the number of red blood cells. Polycythaemia vera, one of the main types, usually starts later in life, on average at 60.
What is it?
Myeloproliferative neoplasms (MPNs) are a group of diseases in which the bone marrow makes too many red blood cells, white blood cells or platelets. Usually one kind of cell is affected most. The main types are polycythaemia vera (too many red cells), essential thrombocythaemia (too many platelets) and primary myelofibrosis (the marrow becomes scarred). Chronic myeloid leukaemia also belongs to this group but is described on its own page.
Many people have a change in a gene such as JAK2, CALR or MPL in their marrow cells. In polycythaemia vera, a JAK2 change usually causes the disease, and it is not usually inherited. Polycythaemia vera mostly starts later in life: the average age at diagnosis is 60.
The first signs
Some people have no signs at first, for example with polycythaemia vera, essential thrombocythaemia or myelofibrosis.
- headaches, dizziness, or changes in vision;
- itching, especially after a warm bath or shower;
- a red face, or red, warm, burning or tingling hands and feet;
- fullness or pain under the left ribs;
- tiredness, night sweats, or losing weight without trying.
How doctors find out
A blood test counts your blood cells. Your family doctor may then send you to a blood specialist (haematologist). More blood tests look for the changed JAK2, CALR or MPL gene, and a bone marrow sample, taken with a needle, is checked in a lab.
Current treatment
Treatment depends on the type: for polycythaemia vera, removing blood, low-dose aspirin and hydroxyurea; for essential thrombocythaemia, hydroxyurea or interferon; for myelofibrosis, ruxolitinib or a donor stem cell transplant for some people.
Will it get worse?
Usually slowly, and some cases, particularly polycythaemia vera, need long-term treatment. People with polycythaemia vera may live slightly less long than average, because of the higher risk of heart attack and stroke. Over time, polycythaemia vera can lead to scarring of the marrow (myelofibrosis), and sometimes an MPN can turn into acute leukaemia. In myelofibrosis, how it goes depends on age, blood counts, immature cells in the blood, chromosome changes and symptoms such as fever or weight loss.
Medicines: what helps, and what to watch for
Treatment aims to prevent symptoms and problems such as blood clots. In polycythaemia vera, blood is removed regularly (venesection), about half a litre at a time, like giving blood: often weekly at first, then less often. Low-dose aspirin helps prevent clots. Medicines such as hydroxycarbamide or interferon can lower the number of red blood cells. Ruxolitinib, a targeted medicine, can ease symptoms such as tiredness, night sweats and weight loss in myelofibrosis, and is used in polycythaemia vera if chemotherapy does not work. Some people under 60 with essential thrombocythaemia and no symptoms only need regular checks.
Good to know:
- Interferon is an injection 1 to 3 times a week that you can learn to give yourself, and it can be used in pregnancy; it can cause flu-like symptoms and hair loss;
- In myelofibrosis, anaemia may need blood transfusions or other medicines.
A healthy lifestyle helps too
Healthy lifestyle changes can lower the risk of blood clots. Being overweight or smoking raises the risk, so losing weight and stopping smoking can help.
Surgery, radiotherapy or a transplant, for some people
In myelofibrosis, an enlarged spleen can be removed with surgery or treated with radiotherapy. For some people with myelofibrosis, a stem cell or bone marrow transplant from a donor is an option: strong chemotherapy is followed by healthy blood-forming cells.
Is there a cure?
Treatment usually aims to control the symptoms, not to cure the condition. A bone marrow or stem cell transplant from a donor aims to cure it. It is not suitable for everyone, because it is an intensive treatment with many risks.
Median survival
About 20 years in essential thrombocythemia, 13.5 years in polycythemia vera and 6 years in primary myelofibrosis
Measured in: Patients with essential thrombocythemia, polycythemia vera or primary myelofibrosis from the Mayo Clinic (826 patients)
The figures behind it
Mayo Clinic patients (826, 58% followed until death): median survival 19.8 years in essential thrombocythemia (292 patients), 13.5 years in polycythemia vera (267) and 5.9 years in primary myelofibrosis (267). In primary myelofibrosis (428 Mayo and Italian patients) the median was 16 years with a CALR mutation and 2.3 years in triple-negative patients.
Sources
Written in plain words by Frontlight from these pages:
- NCI PDQ: Chronic Myeloproliferative Neoplasms Treatment (PDQ®) – Patient Version
- NHS: Polycythaemia (including polycythaemia vera)
- NCI PDQ: Myeloproliferative Neoplasms Treatment (PDQ®) – Health Professional Version
- Cancer Research UK (charity): Myeloproliferative neoplasms
- Blood: Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis